Supreme Court double patenting decision worth $40 billion to Amgen
Company set to enjoy eight more years’ exclusivity on $5 billion-a-year blockbuster after the justices opt not to intervene in “gamesmanship” dispute
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.